Device Technologies, a private equity–backed medical supplies company, has announced a significant strategic “bolt-on” acquisition as part of its broader exit process, according to a report by The Australian Financial Review. The move is expected to position the firm at an estimated valuation of around US$1.5 billion as it nears a potential sale in 2026.
Strengthening Presence Across the Asia-Pacific Region
While the target of the acquisition has not been publicly disclosed, sources indicate that the deal will expand Device Technologies’ footprint across the Asia-Pacific region and enhance its product offerings in advanced surgical and diagnostic equipment. This strategic addition is designed to make the company more attractive to prospective buyers during its upcoming ownership transition.
Industry analysts suggest that the move could reinforce Device Technologies’ position as a key player in the med-tech distribution landscape, particularly as demand for high-quality medical devices and healthcare solutions continues to grow in both Australia and New Zealand.
Private Equity Ownership and Growth Strategy
Device Technologies has been under private equity ownership since 2019 and has pursued an aggressive growth strategy centered on acquisitions, innovation investment, and operational efficiency. The company’s approach has been to identify high-potential med-tech businesses and integrate them into its expanding ecosystem to support hospitals, clinics, and healthcare professionals across the region.
In a statement, a company spokesperson said the latest acquisition underscores Device Technologies’ “continued commitment to growth and to delivering cutting-edge medical technologies that improve patient outcomes.”
Positioning for a Major Private Equity Exit
With a diversified portfolio and a strong regional presence, Device Technologies has become one of the largest independent medical technology distributors in the Southern Hemisphere. Analysts believe the company’s scale, product diversity, and established relationships in the healthcare sector make it a highly attractive target for global investors seeking entry into the high-growth healthcare market.
The ongoing sale process, managed by leading investment advisers, is expected to conclude in early 2026. If completed, it could represent one of the largest private equity exits in Australia’s healthcare industry in recent years — underscoring the increasing investor appetite for scalable, innovation-driven healthcare assets.
